Personal information

Emails & domains

Verified email domains

Websites & social links

Research Gate
academic

Other IDs

Scopus Author ID: 57197223304
Scopus Author ID: 57220051256

Keywords

Pharmaceutical technology, Controlled Release, Nanotechnology, Nanoparticles

Countries

Türkiye

Activities

Collapse all

Employment (6)

Anadolu Üniversitesi: Eskişehir, Eskişehir, TR

2020-09-23 to present | Assoc. Prof. Dr. (Faculty of Pharmacy, Pharmaceutical Technology)
Employment
Source: Self-asserted source
A. Alper Ozturk, Alper Öztürk

Anadolu University, Faculty of Pharmacy: Eskişehir, TR

2018-12-18 to 2020-09-23 | Assistant Profesor Doctor (Department of Pharmaceutical Technology)
Employment
Source: Self-asserted source
A. Alper Ozturk, Alper Öztürk

Anadolu University, Faculty of Pharmacy: Eskisehir, TR

2014-10-14 to 2018-12-18 | Research Assist. Dr. (Department of Pharmaceutical Technology)
Employment
Source: Self-asserted source
A. Alper Ozturk, Alper Öztürk

Universidad de Sevilla Facultad de Farmacia: Sevilla, Andalucía, ES

2017-08 to 2017-09 | Researcher DR. (Pharmacy and Pharmaceutical Technology)
Employment
Source: Self-asserted source
A. Alper Ozturk, Alper Öztürk

Universidad de Sevilla Facultad de Farmacia: Sevilla, Andalucía, ES

2016-06 to 2016-09 | Researcher (Pharmacy and Pharmaceutical Technology)
Employment
Source: Self-asserted source
A. Alper Ozturk, Alper Öztürk

Università degli Studi di Cagliari: Cagliari, Sardegna, IT

2012-06 to 2012-09 | Erasmus Training Student (Faculty of Pharmacy)
Employment
Source: Self-asserted source
A. Alper Ozturk, Alper Öztürk

Education and qualifications (2)

Anadolu University, Graduate school of Health Sciences: Eskişehir, TR

2013-09 to 2017-06-12 | Dr (PhD) (Department of Pharmaceutical technology)
Education
Source: Self-asserted source
A. Alper Ozturk, Alper Öztürk

Anadolu University: Eskisehir, TR

2008 to 2013 (Faculty of pharmacy)
Education
Source: Self-asserted source
A. Alper Ozturk, Alper Öztürk

Peer review (1 review for 1 publication/grant)

Review activity for ACS omega. (1)
How many people are using ORCID?